Treatment
Gemcitabine clinical trials
We’re tracking 376 recruiting studies that include Gemcitabine, each written for real people, not researchers, below.
Recruiting studies
- NCT06897644RecruitingPhase 3
Comparing two chemotherapy strategies for advanced pancreatic cancer
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
Aviano, ItalyAges 18 years+ - NCT06960577RecruitingPhase 3
Durvalumab with chemo before and after bladder cancer surgery
This trial tests a combination of durvalumab (an immunotherapy) with standard chemotherapy before and after bladder removal surgery for muscle-invasive bladder cancer. It aims to see if adding durvalumab helps improve outcomes while keeping side effects manageable.
ChermsideAges 18 years+ - NCT06983210RecruitingPhase 2
Combination treatment for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder or urinary tract cancer that has not been treated before. The goal is to see if adding AM80 to standard chemotherapy and immunotherapy works better.
Nagoya, Aichi-kenAges 18–79 - NCT07001540RecruitingPhase 2
Targeted drug combo for relapsed DLBCL
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07043972RecruitingPhase 2
Gemcitabine and carboplatin after EV-pembrolizumab for bladder cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07049055RecruitingPhase 1/Phase 2
EDV nanocell therapy with chemo for advanced pancreatic cancer
This trial tests a new targeted therapy (EDV nanocells) combined with two standard chemotherapy drugs for people with metastatic pancreatic cancer. It is for patients whose cancer has progressed after first-line FOLFIRINOX or NALIRIFOX treatment.
El Segundo, CaliforniaAges 18 years+ - NCT07107750RecruitingPhase 1
New drug combo for untreated advanced bile duct cancer
This trial tests a new targeted drug (emavusertib) combined with standard chemotherapy and immunotherapy for people with advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination is safe and effective.
St Louis, MissouriAges 18 years+ - NCT07144254RecruitingPhase 1
Tegavivint and gemcitabine for relapsed osteosarcoma
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Atlanta, GeorgiaAges 1–30 - NCT07226856RecruitingPhase 2
New combo for advanced pancreatic cancer
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
Scottsdale, ArizonaAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Birmingham, AlabamaAges 18 years+ - NCT07291063Recruiting
Immunotherapy plus chemo for advanced bile duct or gallbladder cancer
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT07359053RecruitingPhase 2
Paclitaxel polymer micelles combo for advanced sarcoma
This trial tests a combination of paclitaxel polymer micelles with other drugs for people with advanced bone or soft tissue sarcoma that has worsened after first-line chemotherapy. The goal is to see if this new formulation can help shrink tumors or slow their growth.
Shanghai, CHAges 12–70 - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT07481383RecruitingPhase 1
Implant device for chemo delivery in advanced pancreatic cancer
This trial tests an implantable device that delivers chemotherapy (gemcitabine) directly to pancreatic tumors. It may offer a new treatment option for people with non-metastatic, advanced pancreatic cancer that cannot be surgically removed.
Ann Arbor, MichiganAges 18 years+ - NCT07668453RecruitingPhase 2
Adebrelimab plus chemo for advanced bile duct cancer
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07310069Enrolling by invitationPhase 2
Testing a new drug combination for advanced gallbladder cancer
This trial tests a combination of two chemotherapy drugs (gemcitabine and nab-paclitaxel) with two immunotherapy drugs (iparomlimab and tuvorilimab) for people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink the cancer or slow its growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06929286RecruitingPhase 3
Gene therapy vs standard care for bladder cancer after BCG fails
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
Baltimore, MarylandAges 21 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT05548296RecruitingPhase 2
ACR-368 for high-grade endometrial cancer after prior treatments
This Phase 2 trial studies ACR-368 for people with high-grade endometrial cancer that has spread or grown despite at least one prior treatment. It may help by testing whether this drug can better control the cancer after other therapies have not worked.
Mobile, AlabamaAges 18 years+ - NCT07621718RecruitingPhase 3
Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Tucson, ArizonaAges 18 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07283705RecruitingPhase 2
Study of BMS-986504 for MTAP-deleted pancreatic cancer
This trial tests a new drug, BMS-986504, in people with pancreatic cancer that has a specific genetic change called MTAP deletion. The study aims to see if this drug can help shrink or control the tumor.
Houston, TexasAges 18 years+ - NCT06741644RecruitingPhase 1/Phase 2
CS2009 for advanced solid tumors
This trial tests a new drug called CS2009 for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Gemcitabine?
- Yes. Clin2 currently lists 376 recruiting studies that include Gemcitabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Gemcitabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Gemcitabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Gemcitabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.